Track topics on Twitter Track topics that are important to you
CINCINNATI, July 11, 2018 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ:OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare neurol...
The annual ACMG Foundation Day of Caringis sponsored by the ACMG Foundation for Genetic and Genomic Medicine, a prominent national non-profit genetics foundation based Read more...
A fragile supply chain of antibiotics leads to shortages, resistance, and poses a security threat. A new white paper from Access to Medicine explains.
(National Science Foundation) Today, President Donald J. Trump's Fiscal Year (FY) 2019 budget request for the National Science Foundation (NSF) was presented to Congress. More information on the FY 20...
(National Science Foundation) The National Science Foundation (NSF) has renewed support for the National High Magnetic Field Laboratory (MagLab) with $184 million over the next five years, a funding i...
(National Foundation for Cancer Research) Two National Foundation for Cancer Research scientists are among the National Academy of Inventors' latest class. The honor recognizes top academic inventors.
In response to the mass shooting, the Foundation, the National Center, and GoFundMe are collaborating to serve victims by maximizing resources and ensuring a victim-centered, Read more...
Tetra Discovery Partners today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for BPN14770 for the treatment of Fragile X Syndrome....
ēsika 3-in-1 Pro Make Up Foundation SPF 20
Sheer Cover Mineral Foundation SPF-15
CPB Silky Cream Foundation I
cle de peau BEAUTE Cream Foundation I
SHISEIDO Perfect Refining Foundation
To determine frequency of fragile X associated premature ovarian insufficiency (FXPOI) among Turkish premutation carriers.
This is a single center study at the UC Davis MIND Institute in patients age 3.5-16 years of age with fragile X syndrome (FXS), funded by a National Fragile X Foundation Grant. It is a con...
The purpose of this study is to determine whether NNZ-2566 is safe and well tolerated in the treatment of Fragile X Syndrome in adolescent and adult males.
This randomized, double-blind multiple ascending dose study will evaluate the safety and tolerability, pharmacokinetics and efficacy of RO4917523 in patients with Fragile X Syndrome. The p...
This study is a controlled trial of metformin in individuals with fragile X syndrome between the ages of 6 and 25 years. Participants will be randomized in a double-blind design to either ...
This study will evaluate the safety, tolerability and efficacy of multiple doses of AFQ056 in patients with Fragile X Syndrome. The dose range will be 50 to 150 mg b.i.d. The primary read...
Tetra Discovery Partners is a clinical stage biotechnology company developing a portfolio of therapeutic products that will bring clarity of thought to people suffering from Alzhe...
The Cystic Fibrosis Foundation is the world's leader in the search for a cure for cystic fibrosis. The Foundation funds more CF research than any other organization and nearly every CF drug available ...
The National Sleep Foundation is dedicated to improving health and wellbeing through sleep education and advocacy. It is well known for its annual Sleep in AmericaÂ® poll. The F...
We have published hundreds of National Fragile X Foundation news stories on BioPortfolio along with dozens of National Fragile X Foundation Clinical Trials and PubMed Articles about National Fragile X Foundation for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of National Fragile X Foundation Companies in our database. You can also find out about relevant National Fragile X Foundation Drugs and Medications on this site too.